Cefpodoxime Proxetil and Potassium Clavulanate Tablets
KIPOD-CV 325
Cefpodoxime Proxetil 200 mg
Clavulanic Acid 125 mg
Clinical Indications for KIPOD-CV 325:
- Highly active against a wide-spectrum range of gram + ve & gram -ve bacteria.
- Achieves high penetration in lung tissues.
- Achieves superior bacteriological eradication rates & clinical cure rates 95% compared to Cefacor 91% in sinusitis.
- Clavulanic acid acts synergistically with Cefpodoxime to inhibit beta-lactamase-producing organisms.
- Highly active against beta-latamase-producing N. gonorrhoeae, H. influenzae, E. coli, Salmonella typhi & Shigella sonnei.